Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

BRIC Diabetes Care Devices Market (2020 to 2025) – High Prevalence of Diabetes Presents Opportunities

Published

on

Dublin, July 01, 2020 (GLOBE NEWSWIRE) — The “Diabetes Care Devices Market by Type (SMBG, CGMS, Lancets, Insulin Pumps, Insulin Pens, Insulin Syringes, Mobile Apps), Patient Care Settings (Hospitals & Specialty Clinics, Self & Home Care), and Country (Brazil, Russia, India, China) – Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.The growth in this market is primarily attributed to the sharp increase in diabetes, increasing awareness of diabetes management due to the rising number of diabetes awareness campaigns and screening camps, favorable national health strategies, and government-led endorsement of medical devices.By type, under the insulin delivery devices segment, insulin pens to hold the largest share during the forecast periodWithin the type category, the diabetes care devices (BRIC) market has been segmented into blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. Within the insulin delivery devices segment, insulin pens held the largest share in the market. The increasing affordability of insulin pens, convenience, ease-of-use, and technological advancements in these devices that promote integrated diabetes management support the growth of this segment.By end-user, the self/ home healthcare segment is expected to grow at a higher rate during the forecast period (2020-2025)Based on end-user, the diabetes care devices (BRIC) market has been segmented into hospital & specialty clinics and self/home healthcare. The self/home healthcare segment is expected to grow at a higher CAGR due to the increasing awareness of self-management of diabetes, increasing portability of diabetes care devices, and technological innovations that provide real-time insights for patients and healthcare providers for decision-making regarding diabetes control and treatment planning.India is projected to grow at the highest CAGRChina is expected to account for the largest share of the diabetes care devices (BRIC) market in 2019. The large share of this region can primarily be attributed to the sharp increase in the diabetic population in the past decade and endorsements of medical devices by the government. On the other hand, India is expected to witness the highest CAGR during the forecast period due to the increasing government investment in the medical devices industry, high prevalence of type 1 and gestational diabetes cases, and increasing diabetes awareness creation through campaigns and screening camps.Key Topics Covered:
1 Introduction2 Research Methodology
3 Executive Summary4 Premium Insights
4.1 Diabetes Care Devices Market Overview
4.2 Diabetes Care Devices (Bric) Market: Geographic Growth Opportunities
4.3 Diabetes Care Devices (Bric) Market: Country Mix (2020-2025)
5 Industry Insights
5.1 Industry Trends
5.1.1 Growing Demand for Hybrid Closed-Loop Systems/Artificial Pancreas Device Systems
5.1.2 Smart Glucose Meters Enable Integrated Diabetes Management Solutions
5.1.3 Smart Insulin Pen Synchronization with Glucose Monitoring Systems Promotes Diabetes Data Sharing
5.1.4 Innovative Insulin Delivery Systems
5.2 Regulatory Analysis
5.2.1 China
5.2.2 India
5.2.3 Brazil
5.2.4 Russia
5.3 Covid-19 Impact on the Diabetes Care Devices (Bric) Market
6 Diabetes Care Devices Market, by Type
6.1 Introduction
6.2 Blood Glucose Monitoring Systems
6.2.1 Self-Monitoring Blood Glucose Monitoring Systems
6.2.1.1 Technological Innovations to Drive the Growth of Self-Monitoring Blood Glucose Monitoring Systems
6.2.2 Continuous Glucose Monitoring Systems
6.2.2.1 Increasing Collaborations, Partnerships, and Agreements Between Companies to Develop Integrated Cgm Systems to Drive the Growth of This Market
6.2.3 Test Strips/Test Papers
6.2.3.1 Shift Toward Non-Invasive Methods for Blood Glucose Monitoring to Restrain the Growth of This Market during the Forecast Period
6.2.4 Lancets/Lancing Devices
6.2.4.1 Rising Focus to Reduce the Chances of Infection and Accidental Pricking to Increase the Popularity of Safety Lancets during the Forecast Period
6.3 Insulin Delivery Devices
6.3.1 Insulin Pumps
6.3.1.1 Insulin Pumps Integrated with Continuous Glucose Monitoring Systems Offer the Benefits of Data Integration and Diabetes Management
6.3.2 Insulin Pens
6.3.2.1 the Convenience of Use of Insulin Pens and Increasing Affordability could Drive the Growth of This Segment during the Forecast Period
6.3.3 Insulin Syringes and Needles
6.3.3.1 Safety Concerns and Increasing Awareness of Affordable Alternatives in the Market could Restrain the Growth of This Segment during the Forecast Period
6.4 Diabetes Management Mobile Applications
6.4.1 Growing Adoption of Blood Glucose Tracking Apps and Increasing Awareness of Diabetes Among Patients to Drive Market Growth
7 Diabetes Care Devices Market, by Patient Care Settings
7.1 Introduction
7.2 Self/Home Healthcare
7.2.1 Increasing Affordability of Self-Monitoring Systems and Insulin Delivery Devices Has Fueled the Preference for Self/Home Healthcare
7.3 Hospitals & Diabetes Specialty Clinics
7.3.1 Rising Demand for Poc Testing in Hospitals Boosts the Market Growth
8 Diabetes Care Devices Market in BRIC Countries
8.1 Introduction
8.2 China: Diabetes Care Devices Market
8.2.1 Introduction
8.2.2 Market Drivers
8.2.2.1 Sharp Increase in Diabetes in the Past Decade
8.2.2.2 Favorable National Health Strategies
8.2.2.3 Government-Led Endorsement of the Medical Device Industry
8.2.3 Market Restraints
8.2.3.1 Traditional Chinese Medicine As an Alternative
8.2.3.2 High Cost of Advanced Diabetes Management Devices
8.2.4 Market Opportunities
8.2.4.1 Significant Advancements and Leveraging of Artificial Intelligence and Big Data
8.2.5 Market Challenges
8.2.5.1 Lack of Adherence of Patients to Recommended Diabetes Treatment Guidelines
8.3 India: Diabetes Care Devices Market
8.3.1 Introduction
8.3.2 Market Drivers
8.3.2.1 High Prevalence of Diabetes
8.3.2.2 Government’s Make in India Campaign to Encourage Local Manufacturing of Medical Devices
8.3.2.3 Diabetes Awareness Campaigns and Screening Camps
8.3.3 Market Restraints
8.3.3.1 Lack of Accessibility to Healthcare
8.3.3.2 Inadequate Health Insurance Coverage
8.3.4 Market Opportunities
8.3.4.1 Rising Adoption of Mhealth
8.3.5 Market Challenges
8.3.5.1 Shortage of Healthcare Professionals in Diabetes Management
8.4 Brazil: Diabetes Care Devices Market
8.4.1 Introduction
8.4.2 Market Drivers
8.4.2.1 High Prevalence of Diabetes
8.4.2.2 Favorable Government Policies
8.4.3 Market Restraints
8.4.3.1 Lack of Awareness of Diabetes Care
8.4.3.2 High Prices of Advanced Diabetes Care Devices
8.4.4 Market Opportunities
8.4.4.1 Increasing Penetration of Smartphones and Rising Focus on Digital Health to Drive the Growth of Diabetes Management Platforms and Diabetes Management Mobile Applications
8.4.5 Market Challenges
8.4.5.1 Strict Regulatory Guidelines and Regulatory Process for Medical Devices
8.5 Russia: Diabetes Care Devices Market
8.5.1 Introduction
8.5.2 Market Drivers
8.5.2.1 Rising Elderly Population
8.5.2.2 Increasing Rate of Obesity
8.5.3 Market Restraints
8.5.3.1 Large Number of Undiagnosed Diabetics
8.5.4 Market Opportunities
8.5.4.1 Government Spending on Healthcare
8.5.4.2 Rising Investment of Pharma Market Players to Establish Local Manufacturing Plants
8.5.5 Market Challenges
8.5.5.1 Low Adoption of Glucose Monitoring Systems
9 Competitive Landscape
9.1 Overview
9.2 Product Benchmarking
9.3 Geographic Reach of the Top Market Players (2019)
9.4 R&D Expenditure: Key Players in the Diabetes Care Devices (Bric) Market
9.5 Market Share Analysis
9.5.1 Brazil: Diabetes Care Devices Market Share Analysis
9.5.2 Russia: Diabetes Care Devices Market Share Analysis
9.5.3 India: Diabetes Care Devices Market Share Analysis
9.5.4 China: Diabetes Care Devices Market Share Analysis
9.6 Competitive Situation and Trends
9.6.1 Partnerships, Collaborations, and Agreements
9.6.2 Product Approvals, Launches, and Upgrades
10 Company Profiles
10.1 F. Hoffman-La Roche Ltd.
10.2 Abbott
10.3 Ascensia Diabetes Care Holdings Ag
10.4 Dexcom, Inc.
10.5 Medtronic Plc
10.6 B. Braun Melsungen Ag
10.7 Becton, Dickinson and Company
10.8 Acon Laboratories, Inc.
10.9 Arkray, Inc.
10.10 Sanofi
10.11 Novo Nordisk A/S
10.12 Terumo Corporation
10.13 Ypsomed
10.14 Sinocare, Inc.
10.15 Agamatrix Holdings Llc
10.16 Lifescan
10.17 Sd Biosensor, Inc.
10.18 Microgene Diagnostic Systems Pvt. Ltd.
10.19 Dr. Morepen
10.20 Bionime Corporation
10.21 Rossmax International Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/cd1y1nResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending